FLT3 and acute myeloid leukemia: Since 2017, the U.S. Food and Drug Administration (FDA) has approved eight new drugs for the treatment of AML, including the FLT3 inhibitors midostaurin and gicitinib, the IDH inhibitors efusitinib and enalcitinib, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin, CPX351, the hedgehog pathway inhibitor glasdegib, and BCL-2 inhibitor venetoclax.